NCT00906529View on ClinicalTrials.gov

Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin

PHASE4WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

March 31, 2011

Conditions

Type 2 Diabetes

Interventions

DRUG

Levemir (Detemir) and Novolog (Aspart) Insulin

Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal

Trial Locations (1)

75235

Parkland Memorial Hospital, Dallas

Sponsors

Collaborators (1)

Novo Nordisk A/S

All Listed Sponsors

collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT00906529 - Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin | Biotech Hunter | Biotech Hunter